Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventive approaches herald a new era in personalized dementia care.